Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 10/2011

01-10-2011 | Original Paper

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: 7-year follow-up of a rare clinicopathologic syndrome

Authors: R. F. Falkenstern-Ge, M. Kimmich, G. Friedel, A. Tannapfel, V. Neumann, M. Kohlhaeufl

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2011

Login to get access

Abstract

Background

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare clinical pathological syndrome. There have been only 49 cases of DIPNECH reported in the literature so far. We report a case of a 69-year-old nonsmoking man with a 7-year follow-up.

Methods

The initial CT scan from December 2003 showed persistent nonspecific bilateral reticulonodular infiltrates. In January 2004, the patient underwent a video-assisted thoracoscopic wedge resection of his right lower lobe for further diagnostic workup. Pathology of the resected wedge of the right lower lobe revealed a diffuse idiopathic pulmonary cell hyperplasia (DIPNECH) highlighted by staining for the neuroendocrine typical carcinoid markers, such as marker CD 56.

Results

All the performed CT scans over a 7-year period showed no progression of the bilateral pulmonary lesion. The bilateral pulmonary nodules were stable in terms of size, number and form. The yearly control with chest CT scans will be continued.

Conclusions

The neuroendocrine cell hyperplasia is confined to the airway mucosa without penetration through the basement membrane and appears in a diffuse pattern, generally in close association with obliterative bronchiolar fibrosis. DIPNECH is characterized by a mixed obstructive and/or restrictive ventilation pattern with bilateral reticulonodular infiltrates and a predilection for middle-aged women. Little is known about the clinical course and treatment for DIPNECH.
Literature
go back to reference Cohen AJ, King TE, Gilman LB et al (1998) High expression of neutral endopeptidase in idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells. Am J Respir Crit Care Med 158:1593–1599PubMed Cohen AJ, King TE, Gilman LB et al (1998) High expression of neutral endopeptidase in idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells. Am J Respir Crit Care Med 158:1593–1599PubMed
go back to reference Davis SJ, Gosney JR, Hansell DM, Wells AU, Bois RM, Burke MM, Sheppard M, Nicholson AG (2006) Diffuse idiopathic neuroendocrine cell hyperplasia: an under recognised spectrum of disease. Thorax 62(3):248–252 Davis SJ, Gosney JR, Hansell DM, Wells AU, Bois RM, Burke MM, Sheppard M, Nicholson AG (2006) Diffuse idiopathic neuroendocrine cell hyperplasia: an under recognised spectrum of disease. Thorax 62(3):248–252
go back to reference Ginsberg R (2000) Carcinoid tumors. In: Shields TW, LoCicero J, Ponn RB (eds) General thoracic surgery, vol 109. Lippincott Williams and Willkins, Philadelphia, pp 1493–1504 Ginsberg R (2000) Carcinoid tumors. In: Shields TW, LoCicero J, Ponn RB (eds) General thoracic surgery, vol 109. Lippincott Williams and Willkins, Philadelphia, pp 1493–1504
go back to reference Gould VE, Linnoila RI, Memoli VA et al (1983) Neuroendocrine components of the bronchopulmonary tract: hyperplasias, dysplasias, and neoplasms. Lab Invest 49:519–537PubMed Gould VE, Linnoila RI, Memoli VA et al (1983) Neuroendocrine components of the bronchopulmonary tract: hyperplasias, dysplasias, and neoplasms. Lab Invest 49:519–537PubMed
go back to reference Johney EC, Pfannschmidt J, Rieker RJ et al (2006) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and a typical carcinoid tumor. J Thorac Cardiovasc Surg 131:1207–1208PubMedCrossRef Johney EC, Pfannschmidt J, Rieker RJ et al (2006) Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and a typical carcinoid tumor. J Thorac Cardiovasc Surg 131:1207–1208PubMedCrossRef
go back to reference Miller RR, Muller R (1995) Neuroendocrine cell hyperplasia and obliterative bronchiolitis in patients with peripheral carcinoid tumors. Am J Surg Pathol 19:653–658PubMedCrossRef Miller RR, Muller R (1995) Neuroendocrine cell hyperplasia and obliterative bronchiolitis in patients with peripheral carcinoid tumors. Am J Surg Pathol 19:653–658PubMedCrossRef
go back to reference Oberg K (1991) The role of interferons in the management of carcinoid tumors. Acta Oncol 30:519–522PubMedCrossRef Oberg K (1991) The role of interferons in the management of carcinoid tumors. Acta Oncol 30:519–522PubMedCrossRef
go back to reference Saltz L (1993) Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 72:244–248PubMedCrossRef Saltz L (1993) Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 72:244–248PubMedCrossRef
go back to reference Swigris J, Ghamande S, Rice T, Farver C (2005) Diffuse idiopathic neuroendocrine cell hyperplasia: an interstitial lung disease with airway obstruction. J Bronchol 12:62–65CrossRef Swigris J, Ghamande S, Rice T, Farver C (2005) Diffuse idiopathic neuroendocrine cell hyperplasia: an interstitial lung disease with airway obstruction. J Bronchol 12:62–65CrossRef
go back to reference Travis WD, Colby TV, Corrin B, Shimosato Y et al (1999) World Health Organization international histological classification of tumors: histological typing of lung and pleural tumors. Springer, New York Travis WD, Colby TV, Corrin B, Shimosato Y et al (1999) World Health Organization international histological classification of tumors: histological typing of lung and pleural tumors. Springer, New York
Metadata
Title
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: 7-year follow-up of a rare clinicopathologic syndrome
Authors
R. F. Falkenstern-Ge
M. Kimmich
G. Friedel
A. Tannapfel
V. Neumann
M. Kohlhaeufl
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 10/2011
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-011-1015-z

Other articles of this Issue 10/2011

Journal of Cancer Research and Clinical Oncology 10/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.